Disease · MONDO_0004784

allergic asthma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. allergic asthma. Diseases, record MONDO_0004784. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004784

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: allergic asthma; Open Targets
Open Targets ID: MONDO_0004784; Open Targets
Other names: allergic form of asthma; Open Targets
Disease Ontology: DOID:9415; Disease Ontology
Highest stage of its drugs: Phase 3, for 3 of its 39 drugs, from ClinicalTrials.gov and TTD; Open Targets

Drugs39

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
OMALIZUMAB	CHEMBL1201589	Antibody	Phase 3	ClinicalTrials.gov	14	14	14	Drugs and targets
LEVOCETIRIZINE	CHEMBL1201191	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SERATRODAST	CHEMBL70972	Small molecule	Phase 3	TTD	1	0	0	Drugs and targets
DOCONEXENT	CHEMBL367149	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
GAMOLENIC ACID	CHEMBL464982	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
ICOSAPENT	CHEMBL460026	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
FEVIPIPRANT	CHEMBL3137332	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
FLUTICASONE PROPIONATE	CHEMBL1473	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
GSK-2245035	CHEMBL4297492	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
LIGELIZUMAB	CHEMBL2109457	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 39

See all 39 drugs

Targets24

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	13	Glucocorticoid receptor agonist	Phase 2	https://conductscience.org/library/genes/2908	Drugs and targets
IGHE	Immunoglobulin heavy constant epsilon	3	Ig epsilon chain C region inhibitor	Phase 3	https://conductscience.org/library/genes/3497	Drugs and targets
ADRB2	Beta-2 adrenergic receptor	2	Beta-2 adrenergic receptor agonist	Phase 2	https://conductscience.org/library/genes/154	Drugs and targets
PTGDR2	Prostaglandin D2 receptor 2	2	G protein-coupled receptor 44 antagonist	Phase 2	https://conductscience.org/library/genes/11251	Drugs and targets
CHRM1	Muscarinic acetylcholine receptor M1	1	Muscarinic acetylcholine receptor M1 antagonist	Phase 2	https://conductscience.org/library/genes/1128	Drugs and targets
CHRM2	Muscarinic acetylcholine receptor M2	1	Muscarinic acetylcholine receptor M2 antagonist	Phase 2	https://conductscience.org/library/genes/1129	Drugs and targets
CHRM3	Muscarinic acetylcholine receptor M3	1	Muscarinic acetylcholine receptor M3 antagonist	Phase 2	https://conductscience.org/library/genes/1131	Drugs and targets
CHRNA3	Neuronal acetylcholine receptor; alpha3/beta4	1	Neuronal acetylcholine receptor; alpha3/beta4 antagonist	Phase 2	https://conductscience.org/library/genes/1136	Drugs and targets
CHRNA7	Neuronal acetylcholine receptor subunit alpha-7	1	Neuronal acetylcholine receptor protein alpha-7 subunit modulator	Phase 2	https://conductscience.org/library/genes/1139	Drugs and targets
CHRNB4	Neuronal acetylcholine receptor; alpha3/beta4	1	Neuronal acetylcholine receptor; alpha3/beta4 antagonist	Phase 2	https://conductscience.org/library/genes/1143	Drugs and targets

1 to 10 of 24

See all 24 targets

Trials38

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00079937	Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma	Phase 3	628	2011-08-03	Asthma	OMALIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01202903	Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy	Phase 3	616	2015-03-23	Persistent Allergic Asthma	OMALIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02075008	Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201	Phase 2	270	2017-04-25	Asthma	LIGELIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00500539	Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.	Phase 3	155	2011-04-27	Asthma	OMALIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02833974	Effect of the GSK2245035 on the Allergen-induced Asthmatic Response	Phase 2	36	2019-05-15	Asthma	GSK-2245035	Its record names the disease	ClinicalTrials.gov
NCT00829179	Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma	Phase 3	20	2009-10-21	Allergic Asthma	OMALIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01437735	Dose Finding Study for QAW039 in Asthma	Phase 2	1,043		Asthma	FEVIPIPRANT, MONTELUKAST	Its record names the disease	ClinicalTrials.gov
NCT01976208	Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma	Phase 2/3	630		Allergic Asthma	OMALIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01582503	A Study of MEMP1972A in Patients With Allergic Asthma Inadequately Controlled on Inhaled Steroids And A Second Controller (COSTA)	Phase 2	578		Asthma	QUILIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT07352488	Modified Shenling Baizhu Powder for Allergic Asthma With Spleen Deficiency and Dampness Accumulation Syndrome	Not applicable	400		Allergic Asthma	BUDESONIDE, FORMOTEROL FUMARATE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 38

See all 38 trials

Comparisons in its trials10

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Omalizumab vs Placebo: serious adverse events	27 of 421	26 of 207	628	NCT00079937	Trial comparisons
Omalizumab vs Placebo: serious adverse events	8 of 310	11 of 299	609	NCT01202903	Trial comparisons
Omalizumab Treatment Period vs Omalizumab Follow up Period: serious adverse events	14 of 155	1 of 148	303	NCT00500539	Trial comparisons
GSK2245035 20 ng vs Placebo: Number of Participants With Abnormal Urine Analysis Findings	0 of 22	0 of 14	36	NCT02833974	Trial comparisons
GSK2245035 20 ng vs Placebo: Number of Participants With Clinical Chemistry Values of Potential Clinical Concern	2 of 22	1 of 14	36	NCT02833974	Trial comparisons
GSK2245035 20 ng vs Placebo: Number of Participants With Hematology Values of Potential Clinical Concern	14 of 22	9 of 14	36	NCT02833974	Trial comparisons
GSK2245035 20 ng vs Placebo: Number of Participants Receiving Rescue Medication	2 of 22	1 of 14	36	NCT02833974	Trial comparisons
GSK2245035 20 ng vs Placebo: deaths from any cause	0 of 22	0 of 14	36	NCT02833974	Trial comparisons
GSK2245035 20 ng vs Placebo: Number of Participants With Abnormal Peak Expiratory Flow (PEF)	0 of 22	0 of 14	36	NCT02833974	Trial comparisons
GSK2245035 20 ng vs Placebo: serious adverse events	0 of 22	0 of 14	36	NCT02833974	Trial comparisons

Papers from its trials28

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
34429875	RESULT	1	PubMed
34187620	RESULT	1	PubMed
33647073	RESULT	1	PubMed
33099797	RESULT	1	PubMed
32679209	RESULT	1	PubMed
30391954	RESULT	1	PubMed
27253988	RESULT	1	PubMed
27231527	RESULT	1	PubMed
26433533	RESULT	1	PubMed
24934402	RESULT	1	PubMed

1 to 10 of 28

See all 28 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004784

GET https://conductscience.org/api/diseases/v1/MONDO_0004784/drugs?page=2

API reference For AI assistants